OBJECTIVE: In Alzheimer disease (AD), longitudinal changes of beta-amyloid(1-42) (Abeta(1-42)), tau, and phosphorylated tau at threonine 181 (ptau-181) in CSF have been reported in small studies only. We evaluated the natural course of CSF biomarkers in patients with AD, subjective complaints, and mild cognitive impairment (MCI). METHODS: One hundred five patients (50 AD, 38 MCI, 17 subjective complaints) underwent two lumbar punctures, with a mean interval of 21 +/- 9 months. CSF levels of Abeta(1-42), tau, and ptau-181 were measured. RESULTS: CSF Abeta(1-42) and tau levels showed main effects for both diagnosis and time (all p < 0.05), with average increases of 47 +/- 72 and 49 +/- 143 pg/mL. The interaction terms were not significant, which implies a similar time effect for all diagnostic groups. CSF ptau-181 levels showed a main effect for diagnosis (p = 0.01) but not for time (p = 0.27, increase of 1.0 +/- 12 pg/mL). CONCLUSION: Levels of CSF beta-amyloid(1-42) and tau but not phosphorylated tau at threonine 181 increased over time in this memory clinic patient cohort with comparable change in all diagnostic groups. The cross-sectional difference between diagnostic groups, however, exceeded by far the longitudinal changes within individuals, suggesting that these biomarkers are not sensitive as markers of disease progression.
OBJECTIVE: In Alzheimer disease (AD), longitudinal changes of beta-amyloid(1-42) (Abeta(1-42)), tau, and phosphorylated tau at threonine 181 (ptau-181) in CSF have been reported in small studies only. We evaluated the natural course of CSF biomarkers in patients with AD, subjective complaints, and mild cognitive impairment (MCI). METHODS: One hundred five patients (50 AD, 38 MCI, 17 subjective complaints) underwent two lumbar punctures, with a mean interval of 21 +/- 9 months. CSF levels of Abeta(1-42), tau, and ptau-181 were measured. RESULTS:CSF Abeta(1-42) and tau levels showed main effects for both diagnosis and time (all p < 0.05), with average increases of 47 +/- 72 and 49 +/- 143 pg/mL. The interaction terms were not significant, which implies a similar time effect for all diagnostic groups. CSFptau-181 levels showed a main effect for diagnosis (p = 0.01) but not for time (p = 0.27, increase of 1.0 +/- 12 pg/mL). CONCLUSION: Levels of CSF beta-amyloid(1-42) and tau but not phosphorylated tau at threonine 181 increased over time in this memory clinic patient cohort with comparable change in all diagnostic groups. The cross-sectional difference between diagnostic groups, however, exceeded by far the longitudinal changes within individuals, suggesting that these biomarkers are not sensitive as markers of disease progression.
Authors: Wenna Duan; Parshant Sehrawat; Arvind Balachandrasekaran; Ashish B Bhumkar; Paresh B Boraste; James T Becker; Lewis H Kuller; Oscar L Lopez; H Michael Gach; Weiying Dai Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: K Blennow; G De Meyer; O Hansson; L Minthon; A Wallin; H Zetterberg; P Lewczuk; H Vanderstichele; E Vanmechelen; J Kornhuber; J Wiltfang; I Heuser; W Maier; C Luckhaus; E Rüther; M Hüll; H Jahn; H J Gertz; L Frölich; H Hampel; R Pernetzki Journal: J Nutr Health Aging Date: 2009-03 Impact factor: 4.075
Authors: W J P Henneman; H Vrenken; J Barnes; I C Sluimer; N A Verwey; M A Blankenstein; M Klein; N C Fox; P Scheltens; F Barkhof; W M van der Flier Journal: Neurology Date: 2009-09-22 Impact factor: 9.910
Authors: Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski Journal: Lancet Neurol Date: 2010-01 Impact factor: 44.182
Authors: Susan M Landau; Ming Lu; Abhinay D Joshi; Michael Pontecorvo; Mark A Mintun; John Q Trojanowski; Leslie M Shaw; William J Jagust Journal: Ann Neurol Date: 2013-12 Impact factor: 10.422